Multiple groundbreaking studies have advanced understanding and treatment options across cancer types. Amgen presented AMG-410, a pan-KRAS inhibitor targeting diverse KRAS mutations prevalent in solid tumors. Research from University of California, San Francisco, revealed that aggressive triple-negative breast cancers co-opt adjacent fat cells via gap junctions to fuel tumor growth, identifying a potential metabolic vulnerability. Additional discoveries include a novel tubulin inhibitor for chemotherapy, and synergistic drug combinations enhancing gastrointestinal tumor treatment efficacy.